Lisa Diller is a pediatric oncologist and professor of pediatrics at Harvard Medical School. She is a clinician and researcher at the Dana-Farber Cancer Institute, where she leads the program in cancer survivorship, studying late outcomes in long-term survivors and caring for patients.
In the new era of genomic medicine, the use of genetic diagnostics in clinical care of cancer patients and their families is increasingly common and impactful. Technologic advances in gene sequencing have largely outpaced advances in cancer communication, patient and provider education, and decision support in oncology. Diller’s project will involves developing a deep understanding of the state of the art in these critical components of modern genomics, focusing on assessment of the systems already in place for genetic testing and for communication of results. She will engage a multidisciplinary group of informants and collaborators to assess optimizing clinical and educational interventions after genome testing. The goal of Diller’s project is to develop practical clinical models for sharing genomic information in cancer patients and survivors as they age, with a plan to contribute to currently available clinical care guidelines that have largely not addressed these issues. This work has broad implications, given that genomic testing is likely to expand its reach through population-based newborn screening and other clinical indications.
Diller, who earned her MD at UC San Diego School of Medicine, is the chief medical officer of the Dana-Farber/Boston Children’s Cancer and Blood Disorders Center and has practiced as a pediatric oncologist for over 25 years.